curacle co.,ltd. Stock Price

Curacle Co., Ltd., a bio-venture business, engages in the research and development of drugs for diseases caused by aging process and damage to blood vessels. Its products cover age-related vascular diseases, intractable metabolic diseases, and cancer targeting/immunotherapy. The company’s products in pipeline include CU06, which covers treatment and medical indications, such as diabetic macular edema/retinopathy, acute respiratory distress syndrome, myocardial infarction, stroke treatment, concomitantly used with immunotherapy, inflammatory bowel disease treatment, and hereditary angioedema; CU03, which is in Phase 2a clinical trial study for the treatment of age-related macular degeneration; and CU01, a diabetic nephropathy medicine that completed Phase 2a clinical trial. Its products in back-up pipeline include CU02, a product for nonalcoholic steatohepatitis treatment; CU04, a product for the treatment of cancer (c-Myc inhibitor); and CU05, a product for the treatment of cancer (Amigo2-PDK1 inhibitor). The company was founded in 2016 and is based in Seoul, South Korea.